Back to search results

A Study of KB707 for Advanced Lung Cancers and Solid Tumors

This study is testing a new treatment called KB707 for advanced lung cancers and other solid tumors that have spread to the lungs. KB707 is a modified virus designed to boost your body's immune response against cancer. It's given through a nebulizer, which delivers the medicine directly to your lungs. Researchers want to see if KB707 is safe and how well people tolerate it. Some participants may also receive KB707 with Pembrolizumab (KEYTRUDA®), chemotherapy, or Docetaxel. To join, you must be at least 18 years old, have a life expectancy over 12 weeks, and a good performance status. The study is currently unclear on its recruitment status and plans to enroll about 250 people.

Study design
This is a Phase 1/2, open-label study, meaning both you and your doctors will know which treatment you are receiving. It is designed to evaluate the safety, tolerability, and preliminary effectiveness of KB707.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your safety and side effects will be monitored for up to 36 months after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06228326

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

Recruiting
PHASE1Ages 18+InterventionalTreatment
Krystal Biotech, Inc.
~250 participants
Updated 2025-10-24 on ClinicalTrials.gov
What's tested:KB707Pembrolizumab (KEYTRUDA®)ChemotherapyDocetaxel

At a glance

Recruiting sites
10 of 14 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To evaluate the safety and tolerability of inhaled KB707 based upon assessment of adverse events (AE)
Measured over up to 36 months

Conditions

Lung Cancer, Non-small Cell
Lung Cancer Metastatic
Solid Tumor, Adult
Advanced Cancer
Lung Cancer (NSCLC)

Explore related trials

Lung Non-Small Cell CarcinomaSolid Neoplasm

Where it's being run

14 sites across 11 states
California2
Ohio2
Texas2
Alabama1
Arizona1
Florida1
Indiana1
Louisiana1

Study leadership

  • David Chien, MD · STUDY_DIRECTOR · Senior Vice President of Clinical Development

Who to contact

David Chien, MD
[email protected]
412-586-5830
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 years or older at the time of informed consent
Life expectancy \>12 weeks
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Have at least one measurable lung lesion per RECIST v1.1 at Screening
Cohorts 1 through 4 only: Histologically confirmed diagnosis of advanced solid tumor malignancy affecting the lungs and the individual has progressed on standard of care therapy, cannot tolerate standard of care therapy, refused standard of care therapy, or has no standard of care therapy.
Cohorts 5, 6, and 7 only: (1) Histologically or cytologically confirmed diagnosis of stage 3 or 4 NSCLC, as per American Joint Committee on Cancer (AJCC) staging system (8th edition) and (2) Subject must meet the following criteria of prior lines of therapy:

Exclusion

Not fully recovered from prior surgery or radiotherapy, including all radiation-related toxicities
The subject is pregnant, nursing, or plans to become pregnant during study treatment and through three months after the last dose of KB707
Have known history of positive human immunodeficiency virus (HIV 1/2)
Cohorts 5, 6, and 7 only:

What this trial measures

  • To evaluate the safety and tolerability of inhaled KB707 based upon assessment of adverse events (AE)up to 36 months

    Percentage of subjects with treatment-related AEs as assessed by NCI-CTCAE v5